drugset / Trial / NCT00217815

Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer

NCT00217815

Phase 1/2 Completed 20 enrolled NeuTec Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.

Timeline

Start
2005-09
Primary completion
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Efungumab Monoclonal antibody Intravenous
Background Docetaxel Small molecule

Indications